BeOne Medicines Ltd. Reports $1.9 billion Quarterly Revenue

Published November 5, 2026 at 9:23 AM EST

BeOne Medicines Ltd. reported quarterly results highlighted by Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year, according to its earnings release filed with an 8-K Thursday.

BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior year. Diluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarter. Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion. Net product revenues $ 1,855,057 $ 1,395,013 33 % $ 5,022,180 $ 3,805,619 32 %.

Results detail

Further figures in the release included Other revenue $ 34,758 $ 17,271 101 % $ 86,144 $ 39,244 120 %; Total revenue $ 1,889,815 $ 1,412,284 34 % $ 5,108,324 $ 3,844,863 33 %; Adjusted income from operations* $ 612,226 $ 341,184 79 % $ 1,529,649 $ 755,486 102 %; GAAP net income $ 384,706 $ 124,841 208 % $ 849,070 $ 220,431 285 %.

The filing is an Item 2.02 results announcement furnished with Exhibit 99.1. Comparisons use the year-earlier period as presented by BeOne Medicines Ltd. unless the release specifies another baseline. Where both GAAP and non-GAAP metrics appear, both are summarized when the extract includes them.

Segment mix, cash flow and any outlook language in the release are the usual secondary reads after the headline revenue and earnings figures. One-time items—restructuring, impairments, gains on sales or legal settlements—can move GAAP profit without changing the run-rate story, so reconciliations remain essential.

Why it matters

For retail investors, the BeOne Medicines Ltd. print is a check on whether growth, margins and cash generation are moving together. The figures above come from the company’s Exhibit 99.1 earnings materials; how they stack up against the prior-year run rate and any guide published with the release will shape the near-term debate.

By the numbers

Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year
BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior year
Diluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarter
Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion
Net product revenues $ 1,855,057 $ 1,395,013 33 % $ 5,022,180 $ 3,805,619 32 %
Other revenue $ 34,758 $ 17,271 101 % $ 86,144 $ 39,244 120 %

Sources

BeOne Medicines Ltd. Form 8-K with quarterly financial results, filed 2026-11-05 (accession 0001628280-26-070469)

This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.

Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.